We read with great interest the article by Argani and colleagues "TFE3-Fusion variant analysis defines specific clinicopathologic associations among Xp11 translocation cancers" published in June 2016 volume of American Journal of Surgical Pathology. The authors studied 60 Xp11 translocation carcinomas using fluorescence in situ hybridization (FISH) to establish their TFE3 fusion partner.
Of 60 cases, 47 were Xp11 translocation renal cell carcinomas (RCCs). They identified, among others, 5 cases with NONO-TFE3 RCC and described theirs morphologic features.
Tumors were characterized mostly by papillary architecture, with clear to weakly eosinophilic cytoplasm with subnuclear vacuoles leading to distinctive nuclear palisading.